Related Experiment Videos
Glycine-site antagonists and stroke.
1Department of Medicinal Chemistry, Glaxo Wellcome Medicine Centre, via Fleming 4, 37135 Verona, Italy. met7464@glaxowellcome.co.uk
Expert Opinion on Investigational Drugs
|January 5, 2001
Summary
Glycine antagonists targeting the N-methyl-D-aspartate (NMDA) receptor show promise for stroke treatment. By blocking glycine
Area of Science:
- Neuroscience
- Pharmacology
- Stroke Research
Background:
- Excitatory amino acid (S)-glutamic acid is crucial for neuronal processes, acting via ionotropic and metabotropic receptors.
- N-methyl-D-aspartate (NMDA) receptors, a key ionotropic subtype, are implicated in neuronal function and excitotoxicity.
- Stroke involves massive glutamate release, leading to NMDA receptor overactivation and subsequent neuronal cell death.
Purpose of the Study:
- To review the role of the strychnine-insensitive glycine binding site on the NMDA receptor.
- To explore the therapeutic potential of selective glycine antagonists for stroke treatment.
- To categorize existing glycine antagonist chemical structures.
Main Methods:
- Literature review focusing on NMDA receptor function and glycine antagonism.
- Analysis of neurochemical events during stroke, particularly glutamate excitotoxicity.
- Classification of glycine antagonists based on chemical structure.
Main Results:
- NMDA receptor activation requires glycine as a co-agonist.
- Glycine antagonists can prevent NMDA receptor overactivation and subsequent neuronal damage.
- Five main chemical categories of glycine antagonists have been identified.
Conclusions:
- Targeting the glycine binding site on NMDA receptors offers a potential neuroprotective strategy for stroke.
- Development of selective glycine antagonists could mitigate excitotoxicity-induced neuronal death.
- Further research into these antagonist classes may yield effective stroke therapies.